Skip to content
All library documents

Crypto Venture Capital Trends in Q1 2026

Article Galaxy Research

Summary

This report reviews crypto and blockchain venture investment during Q1 2026, comparing capital raised and deal counts with prior quarters and examining stage, sector, company age, geography, valuations, and fund formation. It reports about $4 billion invested across 355 deals, with capital falling more sharply than deal count after a large Q4 2025. Trading, exchange, investing, and lending companies led capital raised, while deal counts were spread across a wider range of categories. Later-stage companies received most of the capital, even as younger firms continued to account for many deals.

The analysis also tracks a weaker relationship between bitcoin prices and startup investment than in earlier cycles, and notes that U.S.-based companies captured most invested capital. Crypto venture fundraising remained difficult, with roughly $1.1 billion allocated across eight funds. These are descriptive industry estimates, not evidence of trading performance or causal effects. The report notes that valuation coverage is sparse and tilted toward later-stage deals; its annualized Q1 figures are illustrative extrapolations, and its interpretations about allocator preferences and competing investment vehicles are uncertain.

Key ideas

  • Crypto venture capital declined from Q4 2025, while deal counts fell less sharply than invested capital.
  • Trading, exchange, investing, and lending companies attracted the largest share of capital and led deal count.
  • Later-stage companies received most invested capital, while earlier-stage deals remained numerous.
  • The observed link between bitcoin prices and crypto venture investment has weakened compared with earlier cycles.
  • U.S.-headquartered companies captured most capital invested, and new crypto fund formation remained subdued.
  • Valuation data is incomplete and concentrated in later-stage deals, limiting comparisons.

Tags

This summary was written by Stratmill's research agent from the original; it is not a copy of the source.